Speaker line up includes:
Meenu Wadhwa, Section Leader, Cytokines and Growth Factors, NIBSC, MHRA
Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
Daniel Sikkema, Executive Director, Head of Immunogenicity and Clinical Immunology, GlaxoSmithKline
Jochem Gokemeijer, Associate Director, Bristol-Myers Squibb
Tim Hickling, Immunogenicity Sciences Discipline Lead, Pfizer
Kees Melief, Chief Scientific Officer, ISA Pharmaceuticals
BENEFITS OF ATTENDING:
鈥� Gain insight into how tackle the challenges involved with the assessment of early risks in immunogenicity
鈥� Hear key feedback from regulatory authorities on how to increase your speed to market
鈥� Participate in insightful discussions on; nanobodies, ADCs, biosimilars and much more!
Meenu Wadhwa, Section Leader, Cytokines and Growth Factors, NIBSC, MHRA
Kei Kishimoto, Chief Scientific Officer, Selecta Biosciences
Daniel Sikkema, Executive Director, Head of Immunogenicity and Clinical Immunology, GlaxoSmithKline
Jochem Gokemeijer, Associate Director, Bristol-Myers Squibb
Tim Hickling, Immunogenicity Sciences Discipline Lead, Pfizer
Kees Melief, Chief Scientific Officer, ISA Pharmaceuticals
BENEFITS OF ATTENDING:
鈥� Gain insight into how tackle the challenges involved with the assessment of early risks in immunogenicity
鈥� Hear key feedback from regulatory authorities on how to increase your speed to market
鈥� Participate in insightful discussions on; nanobodies, ADCs, biosimilars and much more!
